Compare PMA & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PMA | NCEL |
|---|---|---|
| Founded | N/A | 2008 |
| Country | Hong Kong | Switzerland |
| Employees | N/A | 4 |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.0M | 22.0M |
| IPO Year | 2024 | N/A |
| Metric | PMA | NCEL |
|---|---|---|
| Price | $1.25 | $3.42 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 98.6K | 24.8K |
| Earning Date | N/A | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.17 | $1.83 |
| 52 Week High | $1.53 | $5.12 |
| Indicator | PMA | NCEL |
|---|---|---|
| Relative Strength Index (RSI) | 43.90 | 46.05 |
| Support Level | N/A | $2.95 |
| Resistance Level | $1.33 | $3.62 |
| Average True Range (ATR) | 0.08 | 0.29 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 41.34 | 40.59 |
NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.